君聖泰醫藥-B(02511.HK)2024年度淨虧損收窄至3.82億元
格隆匯3月28日丨君聖泰醫藥-B(02511.HK)公佈年度業績,截至2024年12月31日止年度,公司母公司權益持有人應占年內虧損為3.82億元,去年同期虧損9.39億元。研發成本由2023年度的人民幣3.12億元增加16.7%至人民幣3.635億元。
截至2024年12月31日,集團的流動資產為人民幣5.134億元,其中現金及現金等價物為人民幣3.108億元,其他流動資產為人民幣2.026億元。
集團的核心產品熊去氧膽小檗鹼(HTD1801)是一種靶向腸-肝系統的口服抗炎及代謝調節劑,作為熊去氧膽酸和小檗鹼形成的離子鹽,是一種具有獨特雙機制的新分子實體(NME),通過激活AMPK及抑制NLRP3炎症小體發揮其生物學活性。激活AMPK可調控能量穩態,抑制NLRP3炎症小體可緩解系統性炎症,兩種機制協同互補,有效緩解代謝性慢病及心血管疾病。基於此雙重作用機制,集團已獲得有力臨牀數據支持,證實HTD1801具備綜合獲益,包括改善血糖控制、減輕體重、降低血脂(包括致動脈粥樣硬化脂蛋白Lp(a)和ApoB)、降低全身炎症標誌物(包括hsCRP),以及帶來肝臟特異性獲益(包括降低ALT/AST、肝臟脂肪含量及纖維化生物標誌物)。臨牀前研究進一步揭示了HTD1801在防癌、抗衰老及神經保護方面的潛力。集團相信HTD1801有潛力成為一款獨一無二的廣譜代謝調節劑,能夠作為單一療法或與現行已獲批的治療方案聯合使用以治療代謝性疾病,達到最佳治療效果並滿足病患需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.